| 000 | 01719 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516073129.0 | ||
| 264 | 0 | _c20130207 | |
| 008 | 201302s 0 0 eng d | ||
| 022 | _a1099-1069 | ||
| 024 | 7 |
_a10.1002/hon.2005 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKoren-Michowitz, Maya | |
| 245 | 0 | 0 |
_aImatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. _h[electronic resource] |
| 260 |
_bHematological oncology _cDec 2012 |
||
| 300 |
_a200-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xblood |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 |
_aBlast Crisis _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aKidney _xdrug effects |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Chronic-Phase _xdrug therapy |
| 650 | 0 | 4 |
_aLiver _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPatient Compliance |
| 650 | 0 | 4 |
_aPiperazines _xblood |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aPyrimidines _xblood |
| 650 | 0 | 4 | _aTissue Distribution |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aVolchek, Yulia | |
| 700 | 1 | _aNaparstek, Elizabeth | |
| 700 | 1 | _aGavish, Israel | |
| 700 | 1 | _aLevi, Itai | |
| 700 | 1 | _aRowe, Jacob M | |
| 700 | 1 | _aShimoni, Avichai | |
| 700 | 1 | _aNagler, Arnon | |
| 773 | 0 |
_tHematological oncology _gvol. 30 _gno. 4 _gp. 200-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/hon.2005 _zAvailable from publisher's website |
| 999 |
_c21457919 _d21457919 |
||